Insider Buying: Embecta (NASDAQ:EMBC) CEO Acquires $141,000.00 in Stock

Embecta Corp. (NASDAQ:EMBC) CEO Devdatt Kurdikar purchased 30,000 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average cost of $4.70 per share, with a total value of $141,000.00. Following the purchase, the chief executive officer directly owned 804,919 shares in the company, valued at approximately $3,783,119.30. The trade was a 3.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Embecta Stock Down 0.2%

Embecta stock opened at $5.10 on Friday. Embecta Corp. has a 52 week low of $2.77 and a 52 week high of $15.55. The firm’s 50-day simple moving average is $3.50 and its 200 day simple moving average is $6.41. The firm has a market capitalization of $288.97 million, a PE ratio of 3.45 and a beta of 0.81.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Friday, August 7th. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.29. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The firm had revenue of $271.70 million for the quarter, compared to analysts’ expectations of $254.53 million. During the same period in the prior year, the company earned $1.12 EPS. The firm’s revenue was down 8.1% on a year-over-year basis. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, research analysts expect that Embecta Corp. will post 1.84 EPS for the current fiscal year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th will be given a $0.01 dividend. The ex-dividend date is Thursday, August 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.8%. Embecta’s dividend payout ratio is currently 2.70%.

Institutional Investors Weigh In On Embecta

A number of hedge funds and other institutional investors have recently modified their holdings of EMBC. One Wealth Advisors LLC purchased a new position in shares of Embecta during the second quarter valued at approximately $33,000. Bank of America Corp DE grew its stake in Embecta by 45.7% in the 1st quarter. Bank of America Corp DE now owns 374,416 shares of the company’s stock worth $3,310,000 after acquiring an additional 117,448 shares during the period. Amundi raised its holdings in Embecta by 123.3% in the 1st quarter. Amundi now owns 23,798 shares of the company’s stock valued at $210,000 after acquiring an additional 13,139 shares during the last quarter. Parvin Asset Management LLC raised its holdings in Embecta by 11,010.9% in the 1st quarter. Parvin Asset Management LLC now owns 20,333 shares of the company’s stock valued at $180,000 after acquiring an additional 20,150 shares during the last quarter. Finally, Saba Capital Management L.P. lifted its stake in shares of Embecta by 10.3% during the 1st quarter. Saba Capital Management L.P. now owns 384,609 shares of the company’s stock worth $3,400,000 after purchasing an additional 36,000 shares during the period. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EMBC has been the subject of several research reports. Bank of America cut their price objective on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research report on Monday, May 18th. Wall Street Zen cut Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. BTIG Research downgraded Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Zacks Research raised Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Finally, Weiss Ratings downgraded Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Three equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $11.00.

Key Stories Impacting Embecta

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: CEO Devdatt Kurdikar, CFO Jacob Elguicze and director Jeffrey Z. Mann collectively purchased 70,000 shares worth approximately $334,200 on August 12. The insider buying could signal that management and the director believe Embecta’s shares are undervalued after their steep decline. SEC insider transaction filing
• Neutral Sentiment: Embecta also disclosed a quarterly dividend of $0.01 per share, or $0.04 annualized, with a yield of roughly 0.8%. The modest payout is unlikely to be a major near-term stock catalyst but may appeal to income-focused investors. Embecta dividend and insider trading report
• Neutral Sentiment: Multiple law firms, including Hagens Berman, Bronstein Gewirtz & Grossman, Kaplan Fox, Faruqi & Faruqi and Rosen, reminded investors that August 17 is the deadline to seek lead-plaintiff status. The notices target investors who purchased EMBC securities between November 25, 2025, and May 4, 2026, and mostly repeat previously reported information. Hagens Berman class action deadline notice
• Negative Sentiment: The underlying securities class action alleges that Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business and issued misleading fiscal 2026 guidance. If the claims gain traction, the company could face legal expenses, reputational damage and further questions about management credibility. The allegations have not been proven in court. Hagens Berman lawsuit alert

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.